Abstract: The present invention is directed to compounds useful in the treatment of diseases associated with prenylation of proteins and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising same, and to methods for inhibiting protein prenylation in an organism using the same.
Abstract: Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or “linker” defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15 Å, are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.
Type:
Grant
Filed:
November 19, 1999
Date of Patent:
November 18, 2003
Assignees:
The Board of Regents of the University of Texas System, ZymoGenetics Corporation, OsteoScreen
Inventors:
Mark W. Orme, Nand Baindur, Kirk G. Robbins, Scott M. Harris, Maria Kontoyianni, Laurence H. Hurley, Sean M. Kerwin, Gregory Mundy, Charles Petrie
Abstract: The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical dosage form that is not enteric coated or delayed released containing a proton pump inhibitor and a Primary Essential Buffer. When the dosage form is placed in a liquid phase the Primary Essential Buffer maintains the pH of the environment at a value greater than the pKa of the proton pump inhibitor for a time sufficient to substantially avoid acid degradation of the proton pump inhibitor in the environment. Also provided is a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical dosage form; and a kit for the preparation of a liquid oral pharmaceutical composition.
Abstract: The present invention relates to hitherto unknown compounds of formula (I) or their tautomeric forms,
the attachment to the pyridine ring being in the 3- or 4-position, in which formula R stands for one or more substituents which can be the same or different and are selected from the group consisting of: hydrogen, halogen, trifluoromethyl, carboxy, C1-C4 alkyl, alkoxy or alkoxycarbonyl, nitro, amino or cyano and Q stands for C5-C14 divalent hydrocarbon radical which can be straight, branched, cyclic, saturated or unsaturated and X stands for carboxy, C1-C4 alkoxycarbonyl, di(C1-C4 alkoxy)-phosphinoyloxy, amino, C1-C4 alkoxycarbonylamino or tetrahydropyranyloxy; and pharmaceutically acceptable, non-toxic salts and N-oxides thereof. The present compounds are of value in the human and veterinary practice.
Type:
Grant
Filed:
February 4, 2002
Date of Patent:
November 11, 2003
Assignee:
Leo Pharmaceutical Products Ltd. A/S
Inventors:
Charlotte Schou Hunneche, Erik Rytter Ottosen
Abstract: The present invention provides a compound containing at least one sulfhydryl group and at least one NO donor group, wherein said compound contains one or more protected sulfhydryl groups linked to at least one aromatic ring or a heteroaromatic ring with a nitrogen in the ring structure, which ring is substituted by one or more substitutes bearing at least one terminal —ONO2 group. The present invention further provides pharmaceutical compositions comprising one or more of said compounds as an active ingredient.
Type:
Grant
Filed:
January 9, 2002
Date of Patent:
November 4, 2003
Assignee:
Yissum Research Development Company of The Hebrew University
of Jerusalem
Abstract: Compounds of the formula
are useful in the treatment of central nervous system disorders including depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, sexual dysfunction, eating disorders and addictive disorders caused by ethanol or cocaine abuse.
Type:
Grant
Filed:
January 9, 2003
Date of Patent:
September 30, 2003
Assignee:
Wyeth
Inventors:
Gary P. Stack, Megan Tran, Byron A. Bravo
Abstract: The present invention provides certain amide, carbamate and urea derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
Type:
Grant
Filed:
January 23, 2001
Date of Patent:
September 9, 2003
Assignee:
Eli Lilly and Company
Inventors:
Macklin Brian Arnold, David Michael Bender, Thomas John Bleisch, Winton Dennis Jones, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
Abstract: Compounds of the formula:
useful for the treatment of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse and related illnesses.
Abstract: The invention relates to new hydroxyindoles of the Formula,
their use as inhibitors of phosphodiesterase 4 and processes for their preparation.
Type:
Grant
Filed:
January 20, 2003
Date of Patent:
September 2, 2003
Assignee:
Arzneimittelwerk Dresden GmbH
Inventors:
Norbert Höfgen, Ute Egerland, Hildegard Poppe, Degenhard Marx, Stefan Szelényi, Thomas Kronbach, Emmanuel Polymeropoulos, Sabine Heer
Abstract: Compounds of the formula:
useful for the treatment of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse and related illnesses.
Abstract: This invention provides compounds useful in treating serotonin-related central nervous system disorders, including anxiety, generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, sleep disorders, sexual dysfunction, alcohol and drug addiction, Alzheimer's disease, Parkinson's disease, obesity and migraine, the compounds having the general formula:
wherein: R1 and R2 may each be H or an alkyl or alkoxy group; or R1 and R2 may be concatenated to form a bicyclic ring system with the phenyl ring to which they are bound; X is selected from hydrogen, halogen, cyano, C1-C6 alkoxy; Z is (CH2)n or carbonyl; n is 0, 1 or 2; the dashed line indicates an optional double bond; or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
November 15, 2001
Date of Patent:
August 26, 2003
Assignee:
Wyeth
Inventors:
Richard E. Mewshaw, Dahui Zhou, Ping Zhou
Abstract: Crystals of (S)-2[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or salts thereof, useful as excellent antiulcer drugs.
Abstract: A compound of Formula (III):
wherein X is a linkage independently selected from (CH2)12 or (CH2CH2)4O3 and wherein R3 is independently selected from H, CH2CH3, COCH3 or
and acid addition salts, solvates and hydrates thereof. The compounds have unusually high affinity for muscarinic receptors, and exhibit agonist activity useful in the treatment of neurological and other disorders, in which stimulating cholinergic activity is desirable.
Abstract: This invention relates to a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein A and R1 are each an optionally substituted 5 to 6-membered heteroaryl, wherein the heteroaryl is optionally fused to a carbocyclic ring or 5 to 6-heteroaryl; R2 is NH2; R3 and R4 are each hydrogen, halo, (C1-C4)alkyl optionally substituted with halo and the like; and X1 to X4 are each hydrogen, halo, hydroxy, (C1-C4)alkyl optionally substituted with halo and the like. These compounds have COX-2 inhibiting activity and thus useful for treating or preventing inflammation or other COX-2 related diseases.
Abstract: The invention relates to new hydroxyindoles of the Formula,
their use as inhibitors of phosphodiesterase 4 and processes for their preparation.
Type:
Grant
Filed:
February 21, 2002
Date of Patent:
August 5, 2003
Assignee:
Arzneimittelwerk Dresden GmbH
Inventors:
Norbert Höfgen, Ute Egerland, Hildegard Poppe, Degenhard Marx, Stefan Szelényi, Thomas Kronbach, Emmanuel Polymeropoulos, Sabine Heer
Abstract: A process for making amlodipine maleate comprises reacting amlodipine or an acid addition salt thereof with maleic acid under an acidic environment to form an amlodipine maleate product. The process allows for the formation of amlodipine maleate substantially free from amlodipine aspartate.
Type:
Grant
Filed:
August 27, 2001
Date of Patent:
July 29, 2003
Assignee:
Synthon BV
Inventors:
Franciscus B. G. Benneker, Pavel Slanina, Frantisek Picha
Abstract: Compounds of the formula
are useful in the treatment of central nervous system disorders including depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, sexual dysfunction, eating disorders and addictive disorders caused by ethanol or cocaine abuse.
Type:
Grant
Filed:
April 24, 2002
Date of Patent:
July 15, 2003
Assignee:
Wyeth
Inventors:
Gary P. Stack, Megan Tran, Byron A. Bravo
Abstract: Hydantoin compounds which are active as glucokinase activators to increase insulin secretion which makes them useful for treating type II diabetes.